Page last updated: 2024-12-06

adinazolam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

adinazolam: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

adinazolam : A triazolo[4,3-a][1,4]benzodiazepine having a dimethylaminomethyl group at the 1-position, a phenyl group at the 6-position and a chloro substituent at the 8-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID37632
CHEMBL ID328250
CHEBI ID251412
SCHEMBL ID35430
MeSH IDM0118624

Synonyms (37)

Synonym
u-41,123
CHEMBL328250
adinazolam
deracyn
u-41123
PDSP1_000522
D02770
adinazolam (usan/inn)
37115-32-5
PDSP2_000520
8-chloro-1-((dimethylamino)methyl)-6-phenyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine
DB00546
adinazolam [usan]
u 41,123
adinazolamum [inn-latin]
u 41123
4h-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine-1-methanamine, 8-chloro-n-n-dimethyl-6-phenyl-
adinazolamum
chebi:251412 ,
1-(8-chloro-6-phenyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-n,n-dimethylmethanamine
8-chloro-1-[(dimethylamino)methyl]-6-phenyl-4h-s-triazolo[4,3-a][1,4]benzodiazepine
cas_37115-32-5
nsc_37632
bdbm82439
adinazolam [usan:inn:ban]
unii-kn08449444
kn08449444 ,
adinazolam [mi]
adinazolam [who-dd]
adinazolam [inn]
SCHEMBL35430
({12-chloro-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaen-3-yl}methyl)dimethylamine
DTXSID40190611
(z)-1-(8-chloro-6-phenyl-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-1-yl)-n,n-dimethylmethanamine
EX-A3737
Q4682904
AKOS040759484

Research Excerpts

Overview

Adinazolam is a 1-dimethylaminomethyl triazolobenzodiazepine. It is an effective anxiolytic agent as defined by suppression of stress-induced increases in plasma corticosteroids.

ExcerptReferenceRelevance
"Adinazolam (ADZ) is a benzodiazepine-type new psychoactive substance (NPS) with anxiolytic, anticonvulsant, and antidepressant effects. "( Adinazolam, a Benzodiazepine-Type New Psychoactive Substance, Has Abuse Potential and Induces Withdrawal Symptoms in Rodents.
Donio, AL; Hwang, SB; Jang, CG; Kim, SK; Kim, YJ; Kook, WA; Lee, JG; Lee, SY; Lee, Y; Min, HW, 2023
)
3.8
"Adinazolam, which is a 1-dimethylaminomethyl triazolobenzodiazepine, is an effective anxiolytic agent as defined by suppression of stress-induced increases in plasma corticosteroids. "( Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine.
Barsuhn, C; Hester, JB; Lahti, RA; Sethy, VH, 1983
)
1.97
"Adinazolam is a triazolobenzodiazepine, currently under clinical investigation, that possesses antidepressant and anxiolytic activity. "( Urinary screening for adinazolam and its major metabolites by the Emit d.a.u. and FPIA benzodiazepine assays with confirmation by HPLC.
Bryan, W; Fraser, AD; Isner, AF,
)
1.89
"Adinazolam is a triazolobenzodiazepine with anxiolytic and antidepressant activity. "( Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics.
Brouwer, KL; Dukes, GE; Fleishaker, JC; Hak, LJ; Koruda, M; Songer, SS; Suttle, AB, 1992
)
2.03
"Adinazolam (ADI) is a new benzodiazepine with anxiolytic and antidepressant properties. "( Effects of adinazolam on plasma catecholamine, heart rate and blood pressure responses in stressed and non-stressed rats.
Greenberg, IJ; Hershock, DM; Krieman, MJ; Vogel, WH, 1992
)
2.12
"Adinazolam is a new triazolobenzodiazepine bearing an alkyl-amino side chain. "( Influence of repeated administration of cimetidine on the pharmacokinetics and pharmacodynamics of adinazolam in healthy subjects.
Cox, S; Desager, JP; Harvengt, C; Hulhoven, R, 1988
)
1.93

Effects

ExcerptReferenceRelevance
"Adinazolam and U-43,465F have been previously shown to have antidepressant activity in classical screening tests."( Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine.
Barsuhn, C; Hester, JB; Lahti, RA; Sethy, VH, 1983
)
1.25

Treatment

Adinazolam treatment did not alter the platelet shape change response. Sedation was the only treatment-emergent symptom that occurred more frequently in patients treated with adinazlam-SR than placebo.

ExcerptReferenceRelevance
"Adinazolam treatment did not alter the platelet shape change response."( Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers.
Fleishaker, JC; Hauger, RL; Hubbell-Alberts, E; Rausch, JL; Stahl, SM, 1993
)
1.24
"Treatment with adinazolam-SR was well tolerated, with sedation the only treatment-emergent symptom that occurred more frequently in patients treated with adinazolam-SR than placebo."( Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy.
Carter, CS; Denahan, AQ; Fawcett, J; Hertzman, M; Jones, W; Maddock, RJ; Papp, LA; Patterson, WM; Swinson, RP; Weise, CC, 1995
)
2.07

Toxicity

ExcerptReferenceRelevance
" The results show that adinazolam is safe and more effective than placebo for the treatment of major depression."( Double-blind efficacy and safety study comparing adinazolam mesylate and placebo in depressed inpatients.
Glaudin, V; Smith, WT, 1986
)
0.84

Pharmacokinetics

Alprazolam, adinazolam and clonazepam share the typical pharmacological effects of benzodiazepines yet are diverse in their pharmacokinetic properties.

ExcerptReferenceRelevance
" Adinazolam half-life was prolonged approximately 40% in the elderly after oral dosing."( Pharmacokinetics and pharmacodynamics of adinazolam and N-desmethyladinazolam after oral and intravenous dosing in healthy young and elderly volunteers.
Ekernäs, SA; Fleishaker, JC; Grahnén, A; Hulst, LK, 1992
)
1.46
" Pharmacodynamic alterations were assessed using card sorting, digit-symbol substitution, and short-term memory tests."( Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics.
Brouwer, KL; Dukes, GE; Fleishaker, JC; Hak, LJ; Koruda, M; Songer, SS; Suttle, AB, 1992
)
0.58
"Alprazolam, adinazolam, and clonazepam share the typical pharmacological effects of benzodiazepines yet are diverse in their pharmacokinetic properties."( Pharmacokinetics, pharmacodynamics, and treatment issues of benzodiazepines: alprazolam, adinazolam, and clonazepam.
DeVane, CL; Lydiard, RB; Ware, MR, 1991
)
0.88
" Pharmacokinetic parameters were estimated by noncompartmental methods."( Comparison of adinazolam pharmacokinetics and effects in healthy and cirrhotic subjects.
Fleishaker, JC; Kroboth, PD; Maxwell, RA; Smith, RB; Van Thiel, DH, 1991
)
0.64
" Daily dose had no significant effect on dose-normalized AUC and Cmax for AD."( Multiple-dose pharmacokinetics and pharmacodynamics of adinazolam in elderly subjects.
Fleishaker, JC; Phillips, JP; Smith, RB; Smith, TC, 1989
)
0.52
" A pharmacokinetic and pharmacodynamic study was performed on the third day at each dose."( Influence of repeated administration of cimetidine on the pharmacokinetics and pharmacodynamics of adinazolam in healthy subjects.
Cox, S; Desager, JP; Harvengt, C; Hulhoven, R, 1988
)
0.49
" Pharmacokinetic parameters, such as these clearances, had large intersubject variations."( Single dose and steady-state pharmacokinetics of adinazolam after oral administration to man.
Albert, KS; Natale, RB; Rogge, MC; Szpunar, GJ; Wagner, JG,
)
0.39
" NDMAD AUC (2541 +/- 457 versus 2798 +/- 447 ng h ml-1) and Cmax (173 +/- 30."( The lack of effect of smoking on the pharmacokinetics and pharmacodynamics of adinazolam and N-demethyladinazolam.
Chambers, JH; Fleishaker, JC, 1994
)
0.52
" NDMAD Asians had significantly higher NDMAD Cmax and AUC than Caucasians and African-Americans."( The pharmacokinetics and pharmacodynamics of adinazolam: multi-ethnic comparisons.
Ajir, K; Anderson, D; Chambers, JH; Fleishaker, JC; Lin, KM; Nuccio, I; Poland, RE; Smith, M; Zheng, Y, 1997
)
0.56
"The objective of this study was to evaluate a physiologically based pharmacokinetic (PBPK) approach for predicting the plasma concentration-time curves expected after intravenous administration of candidate drugs to rodents."( Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study.
Burton, PS; Crivori, P; Germani, M; Poggesi, I; Rocchetti, M; Smith, ME; Wilson, AG, 2007
)
0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"Effects on psychomotor and cognitive performance of adinazolam (15 or 30 mg), alone and in combination with ethanol (0."( Effects of adinazolam and diazepam, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers.
Eckardt, MJ; Granger, A; Greenblatt, DJ; Lane, E; Linnoila, M; Lister, R; Moss, H; Stapleton, JM, 1990
)
0.92

Bioavailability

ExcerptReferenceRelevance
" In vivo/in vitro relationships from two bioavailability studies were thoroughly evaluated."( In vitro and in vivo evaluation of whole and half tablets of sustained-release adinazolam mesylate.
Borin, MT; Cooper, AM; Fleishaker, JC; Skoug, JW, 1991
)
0.51
" The absolute bioavailability (F), calculated as the dose-corrected ratio of oral to iv adinazolam area under the curve (AUC) values, was found to be 39%."( Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteers.
Fleishaker, JC; Friedman, H; Pollock, SR, 1991
)
0.75
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36

Dosage Studied

Four-week, randomized, double-blind, multicenter study compared the efficacy and safety of adinazolam-SR, at three dosage levels, with placebo. Plasma samples collected during a single dosing interval in each dosing period (3 days) were assayed by high-performance liquid chromatography (HPLC)

ExcerptRelevanceReference
" Comparison of the dose-response curves demonstrated a difference in the intensity of the stimulus effects."( The discriminative stimulus effects of diazepam in rats at two training doses.
Franklin, SR; Tang, AH, 1991
)
0.28
" Adinazolam and NDMAD pharmacokinetics were linear throughout the dosage range studied."( Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in healthy volunteers.
Fleishaker, JC; Phillips, JP, 1989
)
2.63
" Plasma samples collected during a single dosing interval in each dosing period (3 days) were assayed for adinazolam and monodesmethyl adinazolam (NDMAD) by high-performance liquid chromatography (HPLC)."( Multiple-dose pharmacokinetics and pharmacodynamics of adinazolam in elderly subjects.
Fleishaker, JC; Phillips, JP; Smith, RB; Smith, TC, 1989
)
0.74
" This four-week, randomized, double-blind, multicenter study compared the efficacy and safety of adinazolam-SR, at three dosage levels, with placebo."( A fixed-dose study of adinazolam-SR tablets in generalized anxiety disorder.
Cohn, JB; DeFrancisco, DF; Heiser, JF; Linden, RD; Morrissey, JL; Ryan, PJ; Wilcox, CS, 1994
)
0.82
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
sedativeA central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
anxiolytic drugAnxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions.
anticonvulsantA drug used to prevent seizures or reduce their severity.
antidepressantAntidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
triazolobenzodiazepineAny organic heterotricyclic compound that is any benzodiazepine which is ortho-fused with a triazole.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (47)

Assay IDTitleYearJournalArticle
AID113646Effect on the antagonism of nicotine-induced tonic-extensor convulsions (TE) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID113652Effect of test compound on the potentiation of apomorphine-induced gnawing (AG) in aggregated mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID113650Effect on the antagonism of pentylenetetrazole-induced clonic convulsions (P)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID113642Effect on the antagonism of bicuculline-induced tonic-extensor convulsions (B)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID1136396Antidepressant activity in ip dosed albino CF-1 mouse assessed as inhibition of ethanol-induced response1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID114396Tested for antagonism of pentylenetetrazole-induced clonic convulsions (P) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID114393Tested for antagonism of nicotine-induced death (D) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1136393Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of thiosemicarbazide-induced seizures1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID114392Tested for antagonism of bicuculline-induced tonic-extensor convulsions (B) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1136387Effect on motor activity in ip dosed albino CF-1 mouse by traction test1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID227699Virtual screen for compounds with anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID113658Effect on the prolongation of hypoxic survival time (HS)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID1136394Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of strychnine-induced seizures1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID113644Effect on the antagonism of nicotine-induced death (D)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID113656Effect on the potentiation of yohimbine-induced toxicity (Y) in aggregated mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID114561Tested for potentiation of gamma-butyrolactone induced sleep (gamma-B) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID1136397Anxiolytic activity in ip dosed albino CF-1 mouse under hypoxic stress1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID114562Tested for potentiation of yohimbine toxicity in aggregated mice(Y)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID114395Tested for antagonism of oxotremorine hypothermia (OX) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1136395Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of maximal electric shock-induced seizures1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID1136390Effect on motor activity in ip dosed albino CF-1 mouse by pedestal test1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID1136392Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of pentylenetetrazole-induced seizures1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID114394Tested for antagonism of nicotine-induced tonic extensor convulsions (TE) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID113648Effect on the antagonism of oxotremorine-induced hypothermia (OX)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1136391Anticonvulsant activity in ip dosed albino CF-1 mouse assessed as inhibition of nicotine-induced seizures1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1136389Effect on motor activity in ip dosed albino CF-1 mouse by dish test1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID114563Prolongation of hypoxic survival time (HS) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID114565Tested for stereotyped gnawing and licking behavior of mice pretreated with apomorphine (AG)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1136388Effect on motor activity in ip dosed albino CF-1 mouse by chimney test1978Journal of medicinal chemistry, Dec, Volume: 21, Issue:12
Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID113655Effect on the potentiation of gamma-butyrolactone-induced sleep (gamma-B)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (84)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (41.67)18.7374
1990's37 (44.05)18.2507
2000's9 (10.71)29.6817
2010's1 (1.19)24.3611
2020's2 (2.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.87 (24.57)
Research Supply Index4.88 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials37 (39.78%)5.53%
Reviews2 (2.15%)6.00%
Case Studies3 (3.23%)4.05%
Observational0 (0.00%)0.25%
Other51 (54.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]